BRIEF-Puretech Health Says Trem-Cel+ Mylotarg Demonstrated Engraftment, Shielding, Broadened Therapeutic Window, And Patient Benefit

Reuters09-06

Sept 6 (Reuters) - PureTech Health PLC :

* PURETECH HEALTH: TREM-CEL + MYLOTARG DEMONSTRATED ENGRAFTMENT, SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT

* PURETECH HEALTH - VCAR33$(ALLO)$ DEMONSTRATES ENCOURAGING BIOMARKER DATA AT LOWEST DOSE

* PURETECH HEALTH - VOR BIO TO APPROACH U.S. FOOD & DRUG ADMINISTRATION TO DISCUSS A PIVOTAL TRIAL DESIGN FOR TREM-CEL + MYLOTARG BY AROUND YEAR END

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465658114?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-06 14:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465658114","market":"us","top_or_hot":-1,"title":"BRIEF-Puretech Health Says Trem-Cel+ Mylotarg Demonstrated Engraftment, Shielding, Broadened Therapeutic Window, And Patient Benefit","media":"Reuters","content":"<html><body><p>Sept 6 (Reuters) - <a href=\"https://laohu8.com/S/PRTC\">PureTech Health PLC</a>   :</p><p>   * <a href=\"https://laohu8.com/S/PRTC.UK\">PURETECH</a> HEALTH: TREM-CEL + MYLOTARG DEMONSTRATED ENGRAFTMENT, SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT</p><p>   * PURETECH HEALTH - VCAR33<a href=\"https://laohu8.com/S/ALLO\">$(ALLO)$</a> DEMONSTRATES ENCOURAGING BIOMARKER DATA AT LOWEST DOSE</p><p>   * PURETECH HEALTH - VOR BIO TO APPROACH U.S. FOOD &amp; DRUG ADMINISTRATION TO DISCUSS A PIVOTAL TRIAL DESIGN FOR TREM-CEL + MYLOTARG BY AROUND YEAR END</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Puretech Health Says Trem-Cel+ Mylotarg Demonstrated Engraftment, Shielding, Broadened Therapeutic Window, And Patient Benefit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Puretech Health Says Trem-Cel+ Mylotarg Demonstrated Engraftment, Shielding, Broadened Therapeutic Window, And Patient Benefit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 14:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 6 (Reuters) - PureTech Health PLC   :   * PURETECH HEALTH: TREM-CEL + MYLOTARG DEMONSTRATED ENGRAFTMENT, SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT   * PURETECH HEALTH - VCAR33$...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2465658114","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465658114","pubTimestamp":1725602632,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 6  - PureTech Health PLC   :   * PURETECH HEALTH: TREM-CEL + MYLOTARG DEMONSTRATED ENGRAFTMENT, SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT   * PURETECH HEALTH - VCAR33 DEMONSTRATES ENCOURAGING BIOMARKER DATA AT LOWEST DOSE   * PURETECH HEALTH - VOR BIO TO APPROACH U.S. FOOD & DRUG ADMINISTRATION TO DISCUSS A PIVOTAL TRIAL DESIGN FOR TREM-CEL + MYLOTARG BY AROUND YEAR ENDSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","ALLO":"Allogene Therapeutics Inc."},"translate_title":"简介-Puretech Health表示Trem-Cel+Mylotarg证明了植入、屏蔽、拓宽治疗窗口和患者获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1},"content_text":"Sept 6 (Reuters) - PureTech Health PLC   :   * PURETECH HEALTH: TREM-CEL + MYLOTARG DEMONSTRATED ENGRAFTMENT, SHIELDING, BROADENED THERAPEUTIC WINDOW, AND PATIENT BENEFIT   * PURETECH HEALTH - VCAR33$(ALLO)$ DEMONSTRATES ENCOURAGING BIOMARKER DATA AT LOWEST DOSE   * PURETECH HEALTH - VOR BIO TO APPROACH U.S. FOOD & DRUG ADMINISTRATION TO DISCUSS A PIVOTAL TRIAL DESIGN FOR TREM-CEL + MYLOTARG BY AROUND YEAR ENDSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465658114"}